We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

BECKMAN COULTER, INC.

Beckman Coulter develops, manufactures and markets laboratory systems, reagents, centrifugation, lab automation, elec... read more Featured Products: More products

Download Mobile App




Automated PCR Platform Increases Productivity of Clinical Molecular Diagnostic Laboratories

By LabMedica International staff writers
Posted on 09 Dec 2015
Print article
The DxN VERIS Molecular Diagnostics System, a fully automated instrument for the quantitative analysis of molecular targets
The DxN VERIS Molecular Diagnostics System, a fully automated instrument for the quantitative analysis of molecular targets (Photo courtesy of BECKMAN COULTER, INC - Danaher)
An automated real-time PCR platform that has been certified for diagnostics use in Europe (CE-marked) has demonstrated the potential to dramatically improve productivity and turnaround times in the clinical laboratory.

The Beckman Coulter Diagnostics (Nyon, Switzerland) DxN VERIS Molecular Diagnostics System integrates sample introduction, nucleic acid extraction, reaction setup, real-time PCR amplification and detection (using Roche [Basel, Switzerland] TaqMan chemistry), and results interpretation for a fully streamlined workflow. This system offers some important workflow advantages compared to current methods for the determination of viral loads for HIV-1, HCV, HBV, and CMV. For example, the DxN VERIS system allows continuous loading of samples, which eliminates the need for batching and, with true, single sample random access, it allows urgent samples to be added at any time.

As a fully automated system, DxN VERIS decreases the potential for human error and reduces turnaround times considerably compared to the current methods, which allows much faster reporting of results to service users. Unlike current methods, technicians are not required to pipette samples and reagents, which is an important ergonomic advantage. By reducing manual time requirements it enables laboratories to achieve the most from existing staffing levels, helping to maximize productivity within the laboratory.

A case study conducted at the department of clinical microbiology of the University of Barcelona School of Medicine (Spain) demonstrated that the DxN VERIS workflow involved far fewer steps, particularly during the preanalytical stage. It also highlighted the system's reduced hands-on time and lower demand for consumables.

Dr. Jordi Vila, head of the department of clinical microbiology at the University of Barcelona School of Medicine, said, “The implementation of automated methodologies, such as the DxN VERIS, has the potential to improve the quality and delivery of virology services and, for patients, it allows infectious disease results to be obtained at the earliest opportunity with high sensitivity and specificity. In addition to this, consolidation of extraction, amplification, and detection onto a single platform is considered an important factor for laboratories, like ours, where space is very limited.”

Related Links:

Beckman Coulter Diagnostics
Roche
University of Barcelona School of Medicine


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Creatine Kinase-MB Assay
CK-MB Test
New
Blood Gas and Chemistry Analysis System
Edan i500
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.